cGMP: Metabolism and Appetite Modulation

Launched by UNIVERSIDADE NOVA DE LISBOA · Jan 20, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "cGMP: Metabolism and Appetite Modulation," is focused on understanding how a special protein supplement, called casein glycomacropeptide mixed with amino acids (cCGMP-AAs), affects people with a metabolic condition known as phenylketonuria (PKU). PKU is a genetic disorder that makes it difficult for the body to break down a substance called phenylalanine, which is found in many protein-rich foods. The study aims to see how this protein supplement impacts the absorption of amino acids, blood sugar levels, insulin response, and feelings of hunger when consumed alone or with two different meals. The findings may lead to better dietary strategies and improved protein substitutes for people with PKU.

To participate in this trial, you need to be an adult (18 years or older) with a healthy body weight (Body Mass Index between 18.5 and 25.0). You should not have any significant health issues, have not changed your physical activity recently, and should not be taking any protein supplements. Additionally, pregnant or breastfeeding individuals, smokers, or those using drugs are not eligible. If you join the study, you will help researchers gather valuable information that could improve dietary options for others with PKU.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Men or women
• • Adults (age ≥ 18 years)
• • Body Mass Index (BMI) between 18.5-25.0 kg/m2
• • Filling informed consent
• Exclusion Criteria:
• • Clinically significant illness
• • Have changed frequency, duration, or intensity of physical activity in the last month
• • Taking protein supplements
• • Pregnant or breastfeeding
• • Smoking and drug use